VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RVTY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RVTYRevvity, Inc.
$111.21$12.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksRVTYFinancials

Revvity, Inc. (RVTY) Financials

30Y historyFree accessUpdated daily

Revenue growth has stabilized at 7.0% as of 2026Q1, though operating margins remain compressed at 10.7% compared to the 18.1% peak observed in 2024Q4.

RVTY Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue2.9B2.86B2.76B2.75B3.31B3.83B3.78B2.88B2.78B2.26B2.12B2.1B2.24B2.17B2.12B1.92B1.7B1.55B1.96B1.79B1.55B1.47B1.43B1.54B1.5B1.33B1.7B1.36B1.41B1.46B1.43B
Revenue Growth %4.78%3.67%0.16%-16.95%-13.48%1.19%31.18%3.8%23.08%6.69%0.51%-5.92%3.28%2.41%10.09%12.73%9.9%-20.88%9.66%15.58%4.92%3.13%-6.91%2.01%13.15%-21.54%24.37%-3.18%-3.62%2.35%0.54%
Cost of Goods Sold1.41B1.34B1.43B1.43B1.55B1.55B1.79B1.59B1.53B1.23B1.14B1.17B1.27B1.23B1.19B1.1B963.91M851.78M1.12B1.07B922.89M859.29M846.33M906.27M904.1M721.73M918.43M787.3M991.3M1.04B1.01B
COGS % of Revenue-46.92%51.99%51.93%46.84%40.38%47.38%55.16%54.96%54.39%54.04%55.81%56.6%56.61%56.33%57.11%56.56%54.93%57.39%59.99%59.68%58.3%59.22%59.03%60.07%54.26%54.18%57.76%70.41%71.2%70.61%
Gross Profit1.49B1.52B1.32B1.32B1.76B2.28B1.99B1.29B1.25B1.03B972.25M930.03M971.01M939.97M923.81M823.98M740.43M698.98M835.07M715.14M623.47M614.54M582.76M628.95M600.88M608.33M776.84M575.8M416.6M420.7M419.5M
Gross Margin %51.44%53.08%48.01%48.07%53.16%59.62%52.62%44.84%45.04%45.61%45.96%44.19%43.4%43.39%43.67%42.89%43.44%45.07%42.61%40.01%40.32%41.7%40.78%40.97%39.93%45.74%45.82%42.24%29.59%28.8%29.39%
Gross Profit Growth %-14.62%0.04%-24.91%-22.84%14.64%53.94%3.34%21.56%5.87%4.54%-4.22%3.3%1.75%12.12%11.28%5.93%-16.3%16.77%14.7%1.45%5.45%-7.34%4.67%-1.22%-21.69%34.91%38.21%-0.97%0.29%3.07%
Operating Expenses1.13B1.16B912.14M922.7M979.61M941.95M970.72M887.57M880.27M724.72M666.58M663.24M740.51M681.22M723.02M706.04M567.67M558.89M633.76M540.49M471.97M452.83M444.68M495.22M540.87M492.46M592.81M464.4M322.7M332.9M331.8M
OpEx % of Revenue-40.6%33.11%33.55%29.58%24.61%25.66%30.78%31.69%32.11%31.51%31.51%33.1%31.45%34.18%36.75%33.31%36.04%32.33%30.24%30.52%30.72%31.12%32.26%35.94%37.03%34.97%34.07%22.92%22.79%23.25%
Selling, General & Admin914.23M945.28M715.3M706.12M757.99M741.61M765.33M698.24M694.17M585.56M542.8M551.2M619.97M548.69M590.89M590.92M473.86M468.11M524.82M430.57M373.85M365.46M362.32M386.4M431.3M411.14M418.98M327.1M226.3M243.4M290.9M
SG&A % of Revenue-33.1%25.96%25.67%22.89%19.37%20.23%24.21%24.99%25.94%25.66%26.19%27.71%25.33%27.94%30.76%27.8%30.19%26.78%24.09%24.18%24.8%25.35%25.17%28.66%30.91%24.71%24%16.07%16.66%20.38%
Research & Development220.13M215.84M196.84M216.58M221.62M200.34M205.39M189.34M186.1M139.16M123.78M112.04M120.54M132.52M132.14M115.12M93.81M90.78M108.94M109.92M98.12M87.37M82.36M83.14M86.45M81.31M86.12M71.2M46M44.9M0
R&D % of Revenue-7.56%7.14%7.87%6.69%5.23%5.43%6.57%6.7%6.17%5.85%5.32%5.39%6.12%6.25%5.99%5.5%5.85%5.56%6.15%6.35%5.93%5.76%5.42%5.74%6.11%5.08%5.22%3.27%3.07%-
Other Operating Expenses-1000K-1.7M00000000000000000000025.67M23.11M087.72M66.1M50.4M44.6M40.9M
Operating Income360.29M356.63M410.52M399.49M781.12M1.34B1.02B405.48M370.97M304.63M305.67M266.79M230.49M258.76M200.78M117.94M172.76M140.09M201.31M174.65M151.5M161.71M138.09M183.91M123.37M197.58M184.03M104.4M31.7M121.6M87.7M
Operating Margin %12.41%12.49%14.9%14.52%23.59%35.01%26.96%14.06%13.35%13.5%14.45%12.68%10.3%11.95%9.49%6.14%10.14%9.03%10.27%9.77%9.8%10.97%9.66%11.98%8.2%14.86%10.86%7.66%2.25%8.32%6.14%
Operating Income Growth %--13.13%2.76%-48.86%-41.71%31.4%151.5%9.3%21.78%-0.34%14.57%15.75%-10.92%28.88%70.24%-31.73%23.32%-30.41%15.26%15.28%-6.31%17.11%-24.92%49.07%-37.56%7.37%76.27%229.34%-73.93%38.65%6.05%
EBITDA773.26M658.9M838.37M831.26M1.21B1.65B1.27B619.51M551.56M409.63M405.64M372.16M347.23M387.23M327.65M228.86M261.92M220.86M289.92M252.65M220.69M228.71M205.68M273.69M219.48M281.84M311.28M170.5M82.1M166.2M135.9M
EBITDA Margin %26.64%23.07%30.43%30.22%36.48%43.14%33.48%21.48%19.85%18.15%19.17%17.68%15.52%17.88%15.49%11.91%15.37%14.24%14.79%14.14%14.27%15.52%14.39%17.83%14.58%21.19%18.36%12.51%5.83%11.38%9.52%
EBITDA Growth %-6.39%-21.41%0.86%-31.19%-26.84%30.42%104.4%12.32%34.65%0.98%9%7.18%-10.33%18.18%43.16%-12.62%18.59%-23.82%14.75%14.48%-3.51%11.19%-24.85%24.7%-22.13%-9.46%82.57%107.67%-50.6%22.3%14.49%
D&A (Non-Cash Add-back)412.97M302.26M427.85M431.77M427M311.44M246.51M214.03M180.59M105M99.97M105.36M116.74M128.47M126.86M110.92M89.16M80.76M88.61M78M69.18M67M67.6M89.78M96.11M84.26M127.25M66.1M50.4M44.6M48.2M
EBIT361M360.46M412.4M281.79M755.79M1.31B956.08M300.77M324.66M340.66M285.6M246.8M205.87M203.26M96.37M89.14M177.88M120.14M174.03M166.61M159.89M93.95M135.55M133.73M60.02M115.87M184.03M111.4M53.7M55.3M87.7M
Net Interest Income-66.61M-61.08M-23.09M-26.68M-100.37M-99.89M-48.7M-62.13M-65.83M-41.37M-40.83M-37.32M-35.6M-49.27M-45.04M-22.9M-15.06M-14.97M-21.2M000000000000
Interest Income27.33M31.1M73.19M72.13M3.59M2.24M1.01M1.5M1.14M2.57M702K673K667K650K747K1.88M832K1.03M4.02M4.69M9.39M3.32M2.4M00000000
Interest Expense93.94M92.19M96.28M98.81M103.95M102.13M49.71M63.63M66.98M43.94M41.53M38M36.27M49.92M45.79M24.78M15.89M17.16M82.14M41.7M0047.71M105.08M279.72M128.31M74.63M7M064.6M8.9M
Other Income/Expense-94.4M-88.36M-94.39M-216.51M-129.28M-136.42M-113.43M-168.34M-113.28M-7.92M-61.6M-57.98M-60.89M-105.42M-150.19M-53.59M-10.78M-33.96M-52.5M-23.36M-767K-95.05M-38.74M-56.39M-32.87M-163.43M-39.54M-66.5M124.3M-35.8M-7.3M
Pretax Income265.89M268.28M316.13M182.98M651.84M1.2B906.36M237.14M257.68M296.72M244.07M208.81M169.6M153.33M50.59M64.35M161.98M106.14M148.81M151.29M150.74M66.66M99.34M80.88M-8.55M34.15M144.49M44.9M156M54M80.4M
Pretax Margin %9.16%9.39%11.47%6.65%19.68%31.44%23.96%8.22%9.28%13.15%11.54%9.92%7.58%7.08%2.39%3.35%9.5%6.84%7.59%8.46%9.75%4.52%6.95%5.27%-0.57%2.57%8.52%3.29%11.08%3.7%5.63%
Income Tax24.19M25.8M33.05M3.47M139.16M314.15M178.27M9.39M20.21M139.83M28.36M20.02M8.44M-14.59M-17.85M63.18M26.06M31.8M21.04M17.45M32.41M128K23.46M25.87M-4.42M34.77M58.42M16.5M54M23.4M25.9M
Effective Tax Rate %9.1%9.62%10.46%1.9%21.35%26.1%19.67%3.96%7.84%47.12%11.62%9.59%4.97%-9.52%-35.29%98.18%16.09%29.96%14.14%11.54%21.5%0.19%23.62%31.99%51.64%101.82%40.43%36.75%34.62%43.33%32.21%
Net Income240.96M241.68M295.83M-118.38M569.18M943.16M728.1M227.56M238.79M113.02M233.68M212.45M158.04M167.92M68.44M1.17M383.92M85.6M128.41M132.92M117.15M81.75M75.88M52.96M-4.13M-620K90.52M28.4M102M33.7M60.2M
Net Margin %8.3%8.46%10.74%-4.3%17.19%24.64%19.25%7.89%8.6%5.01%11.05%10.09%7.06%7.75%3.24%0.06%22.53%5.52%6.55%7.44%7.58%5.55%5.31%3.45%-0.27%-0.05%5.34%2.08%7.24%2.31%4.22%
Net Income Growth %-22.36%-18.31%349.91%-120.8%-39.65%29.54%219.96%-4.7%111.28%-51.64%9.99%34.43%-5.89%145.36%5739.68%-99.69%348.51%-33.34%-3.39%13.46%43.31%7.73%43.28%1380.75%-566.94%-100.68%218.73%-72.16%202.67%-44.02%10.87%
Net Income (Continuing)241.53M242.48M283.07M179.5M512.68M889.44M728.1M227.75M237.47M156.89M215.71M188.78M161.17M167.92M68.44M1.17M135.92M74.33M127.77M133.83M118.32M66.53M75.88M55.01M-4.13M-620K86.07M28.4M79M9.6M54.5M
Discontinued Operations-743K-975K12.76M-297.88M56.5M53.72M0-195K1.31M-43.87M17.97M23.67M-3.13M000248M11.26M633K-916K-1.17M15.21M000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)2.152.082.41-0.954.508.086.492.042.141.022.121.871.391.480.600.013.250.731.061.100.930.620.580.41-0.03-0.010.890.311.110.370.64
EPS Growth %-16.97%-13.69%353.87%-121.09%-44.31%24.47%218.23%-4.67%110%-51.87%12.98%34.93%-6.08%148.28%5685.44%-99.68%345.21%-31.13%-3.82%19.02%48.54%7.48%41.46%1346.2%--100.64%187.1%-72.07%200%-42.19%25.49%
EPS (Basic)-2.082.41-0.954.518.126.532.052.161.032.131.891.401.500.600.013.280.741.071.120.940.630.600.42-0.03-0.010.920.311.130.370.64
Diluted Shares Outstanding111.88M113.21M122.82M124.81M126.43M116.67M112.08M111.5M111.53M110.86M110.31M113.31M113.74M113.5M114.86M113.86M117.98M116.59M118.69M120.81M125.88M131.43M129.79M129.17M125.57M107.83M101.71M91.3M91.89M91.08M94.8M
Basic Shares Outstanding111.88M113.21M122.76M124.7M126.16M116.17M111.51M110.83M110.56M109.86M109.48M112.51M112.59M112.25M113.73M112.98M117.11M116.25M117.66M118.92M125.2M129.27M127.34M126.09M125.57M104.56M98.39M91.3M90.27M91.08M94.8M
Dividend Payout Ratio-13.57%11.65%-6.21%3.43%4.29%13.65%12.99%27.25%13.18%14.86%20.01%18.82%46.61%2715.78%8.59%38.2%25.76%25.36%30.26%44.4%47.16%66.86%--30.42%89.79%24.9%76.26%44.19%

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Newborn screening volume sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Remains Modestly Positive

According to the latest quarterly income statement data, Revvity achieved a 7.0% year-over-year revenue growth in 2026Q1, signaling a stabilization in top-line performance following the volatility observed in previous periods where growth rates fluctuated between negative 3.7% and positive 5.9% throughout the prior fiscal year.

The recent uptick in revenue growth suggests that the company's transition toward a pure-play life sciences and diagnostics model is beginning to yield more consistent results. However, investors should monitor whether this growth is driven by sustainable organic demand or if it remains susceptible to the lumpy nature of instrument placements and ongoing integration of recent acquisitions.

Gross Margin Volatility Masks Efficiency

As reported in financial statements, Revvity's gross margin reached 54.5% in 2026Q1, though historical data reveals significant quarterly swings, including a notable compression to 42.2% in 2023Q4, which highlights the structural sensitivity of the company's manufacturing cost base to product mix and divestiture-related accounting adjustments.

The fluctuation in gross margins appears to be heavily influenced by the shifting composition of the company's revenue streams between high-margin reagents and lower-margin diagnostic hardware. Sustained margin expansion will likely require a more predictable contribution from the BioLegend portfolio to offset the inherent complexity of the diagnostic instrument manufacturing cycle.

Operating Leverage Remains Under Pressure

Based on Revvity's reported figures, the operating margin stood at 10.7% in 2026Q1, a level that remains below the 18.1% peak observed in 2024Q4, suggesting that the company has yet to achieve the desired operating leverage following its recent corporate restructuring and divestiture of legacy industrial assets.

The current SG&A expense levels, which frequently exceed $240 million per quarter, indicate that the company is still carrying significant overhead costs that may be hindering bottom-line scalability. Investors should investigate whether these expenses are temporary integration costs or if they represent a more permanent structural burden that could limit future earnings growth.

Earnings Quality Impacted by SBC

Data from recent filings indicates that stock-based compensation remains a recurring expense, with $8.7 million recorded in 2026Q1, which continues to exert a measurable impact on net income and complicates the assessment of the company's underlying operational profitability relative to its reported earnings per share.

The variability in net income, which ranged from $27.7 million to $102.7 million over the last ten quarters, suggests that non-operating items and tax adjustments are creating significant noise in the bottom line. Analysts should focus on normalized earnings metrics to better understand the true cash-generating capability of the core business.

RVTY — Frequently Asked Questions

Quick answers to the most common questions about buying RVTY stock.

What was Revvity, Inc.'s (RVTY) revenue in 2025?

For fiscal year 2025, Revvity, Inc. (RVTY) reported total revenue of $2.86B. This represents a 100.1% increase compared to $1.43B in 1996.

Is Revvity, Inc. (RVTY) profitable?

Revvity, Inc. (RVTY) is profitable, generating $241.7M in net income for the fiscal year ending 2025 with a net profit margin of 8.5%.

What is Revvity, Inc.'s operating profit margin?

Revvity, Inc. (RVTY) reported an operating income of $356.6M, resulting in an operating profit margin of 12.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Revvity, Inc.'s gross profit and gross margin?

Revvity, Inc. (RVTY) generated $1.52B in gross profit for the year, representing a gross profit margin of 53.1%. This demonstrates the company's core pricing power and production efficiency.